"Carboplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An organoplatinum compound that possesses antineoplastic activity.
| Descriptor ID |
D016190
|
| MeSH Number(s) |
D02.691.800.338
|
| Concept/Terms |
Carboplatin- Carboplatin
- cis-Diammine(cyclobutanedicarboxylato)platinum II
- CBDCA
|
Below are MeSH descriptors whose meaning is more general than "Carboplatin".
Below are MeSH descriptors whose meaning is more specific than "Carboplatin".
This graph shows the total number of publications written about "Carboplatin" by people in this website by year, and whether "Carboplatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 2 | 3 |
| 1995 | 3 | 4 | 7 |
| 1996 | 4 | 1 | 5 |
| 1997 | 1 | 6 | 7 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 7 | 8 |
| 2000 | 2 | 7 | 9 |
| 2001 | 2 | 7 | 9 |
| 2002 | 3 | 11 | 14 |
| 2003 | 1 | 3 | 4 |
| 2004 | 1 | 13 | 14 |
| 2005 | 4 | 10 | 14 |
| 2006 | 5 | 7 | 12 |
| 2007 | 3 | 7 | 10 |
| 2008 | 3 | 10 | 13 |
| 2009 | 3 | 17 | 20 |
| 2010 | 6 | 17 | 23 |
| 2011 | 2 | 17 | 19 |
| 2012 | 4 | 10 | 14 |
| 2013 | 6 | 15 | 21 |
| 2014 | 4 | 8 | 12 |
| 2015 | 6 | 14 | 20 |
| 2016 | 2 | 13 | 15 |
| 2017 | 5 | 9 | 14 |
| 2018 | 3 | 11 | 14 |
| 2019 | 2 | 20 | 22 |
| 2020 | 4 | 9 | 13 |
| 2021 | 3 | 14 | 17 |
| 2022 | 0 | 10 | 10 |
| 2023 | 1 | 11 | 12 |
| 2024 | 2 | 7 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carboplatin" by people in Profiles.
-
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun. 2024 Oct 01; 4(10):2823-2834.
-
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14. Gynecol Oncol. 2024 Nov; 190:283-290.
-
Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2024 Aug 01; 10(8):1111-1115.
-
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jul 01; 30(13):2751-2763.
-
Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2. Cancer. 2024 Jul 01; 130(13):2361-2371.
-
Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial. Nat Commun. 2024 Feb 23; 15(1):1650.
-
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell. 2024 Mar 11; 42(3):429-443.e4.
-
Dietary Magnesium Replacement for Prevention of Hypomagnesemia in Patients With Ovarian Cancer Receiving Carboplatin-Based Chemotherapy. JCO Oncol Pract. 2024 Apr; 20(4):517-524.
-
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial. Eur J Cancer. 2024 Mar; 200:113580.
-
Angiographic characteristics and treatment approach in patients undergoing intra-arterial chemotherapy for retinoblastoma. Graefes Arch Clin Exp Ophthalmol. 2024 Apr; 262(4):1321-1328.